Arvinas reports $249.7M Q2 revenue, $169.4M net income and guidance into H2 2028
I'm LongbridgeAI, I can summarize articles.Arvinas reported Q2 2026 revenue of $249.7 million and net income of $169.4 million, driven by VEPPANU licensing to Rigel. The company holds $567.9 million in cash, sufficient for operations through H2 2028. Key highlights include FDA approval of VEPPANU, clinical updates on ARV-393, ARV-102, and ARV-027, and preclinical data for ARV-6723. Arvinas anticipates sharing clinical data from its pipeline over the next 12 months.
Arvinas reported second-quarter 2026 revenue of $249.7 million and net income of $169.4 million, driven by collaboration and licensing agreements. The company held $567.9 million in cash, cash equivalents and marketable securities at June 30, 2026 and said those resources are sufficient to fund operations into the second half of 2028. Arvinas highlighted the FDA approval of VEPPANU and a global license to Rigel, alongside multiple upcoming clinical data milestones across its PROTAC pipeline.
Financial Highlights
- Revenue: $249.7 million for the three months ended June 30, 2026 (versus $22.4 million in Q2 2025).
- Cost of license revenue: $9.0 million for the quarter ended June 30, 2026.
- Operating income (Loss) from operations: Income from operations of $164.1 million for the quarter ended June 30, 2026.
- Net income: $169.4 million for the quarter ended June 30, 2026.
- Earnings per share, diluted: $2.58 for the quarter ended June 30, 2026.
- Cash, cash equivalents and marketable securities: $567.9 million as of June 30, 2026 (down from $685.4 million at December 31, 2025); company expects funds to support operations into H2 2028.
Business Highlights
- Regulatory and licensing milestone: VEPPANU (vepdegestrant), the first FDA-approved PROTAC ER degrader, received U.S. approval for ESR1‑mutated ER+/HER2‑ advanced or metastatic breast cancer and was subsequently licensed to Rigel for exclusive global development, manufacturing and commercialization.
- Clinical pipeline activity: Continued Phase 1 dose escalation for ARV-393 (BCL6) with preliminary clinical activity observed in B‑ and T‑cell lymphomas; combination trial with glofitamab enrolling in DLBCL.
- Neurology and rare disease programs: ARV-102 (LRRK2) joined MJFF-supported LITE and PPMI initiatives; ARV-027 (polyQ-AR) completed single-ascending dose cohorts and initiated multiple-dose cohorts in healthy volunteers.
- Immuno-oncology and KRAS programs: Presented preclinical data for ARV-6723 (HPK1 degrader) showing reversal of T-cell exhaustion and efficacy in ICI-resistant models; ARV-806 (KRAS G12D) completed dose escalation with planned initial monotherapy data in 2H 2026 and intention to seek out-licensing for further trials.
- Upcoming clinical/data milestones: Company anticipates sharing clinical data from ARV-393, ARV-102 and ARV-027 over the next 12 months and initiating ARV-6723 Phase 1 enrollment in Q3 2026.
Original SEC Filing: ARVINAS, INC. [ ARVN ] - 8-K - Aug. 04, 2026